Stock Ratings / Health Care / ETRA / earnings

ENTX (40) VALN (58) SRZN (27) RGNX (39) ⌘ Pro Terminal →

Electra Therapeutics Inc. (ETRA) Next Earnings Date & Expected ±12.5% Move

Q: When is ETRA's next earnings date?

Based on SEC filing cadence, Electra Therapeutics Inc. (ETRA)'s next quarterly reporting window is estimated around Upcoming Quarter.

Q: How much is ETRA stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for ETRA, spanning a range between $7.56 and $9.72.

$8.64 -3.79% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.56

Electra Therapeutics Inc. (ETRA) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $542.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $8.56 (-0.87%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-4.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ETRA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (48/100 Composite)

🔍 WHY ETRA SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (25% of score)

SEC XBRL Trailing 12 Months: 0.4% FCF Margin ($15.2M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$9.04-3.2% Next Q

Q2 (-2Q)

Grade C-$8.75-0.5% Next Q

Q3 (-1Q)

Grade C-$8.71-0.8% Next Q

Current

Grade D$8.64-5.6% Hist 90D α

Trajectory: C (56) → D (48)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ETRA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ETRA currently carries a cautious 48/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.00) and Max Pain ($9.07) forces dealer call-delta covering toward $16.28.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ETRA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ETRA Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 48%NO 52%Trade / Inspect Odds →

NEXT EST. WINDOW: Upcoming Quarter (~28 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$1.08 Expected Swing

MODEL EARNINGS SETUP GAUGE

ETRA Quantitative Pre-Earnings Setup: 48/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (48/100)Model Risk Weight (52/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ETRA)

✓Walkthrough of ETRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ETRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -34.79%🛡️ HOLDING TREND SUPPORT

2026-10-30O $8.55H $8.64L $7.95C $8.64VOL 150.5K

SUP: $8.10SMA50: $10.00SMA200: $10.02

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ETRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ETRA Butterfly Map → + Track ETRA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ETRA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ETRA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ETRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ETRA)

Health Care Rank #381 of 1016 ⚔️ ENTX vs ETRA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ETRA vs. ENTX, VALN, SRZN, RGNX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Electra Therapeutics Inc. (ETRA) ranks #381 by composite RQD confidence (48/100, grade D) and #434 by equity capitalization ($542.3M). Within this direct 5-issuer industry benchmark cohort, ETRA leads on earnings valuation at N/A trailing P/E, while ENTX leads on capital efficiency and profitability with -33.6% ROIC and 0.0% gross margin. VALN currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with ETRA at 48/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ETRA ACTIVE Electra Therapeutics Inc.	D	48/100	—	—	—	-3.79%	$542.3M	Benchmark Subject
ENTX Entera Bio Ltd.	D-	40/100	—	0.0%	-33.6%	+0.65%	$542.6M	/entx-vs-etra →
VALN Valneva SE	D+	58/100	—	—	—	-0.52%	$541.8M	/valn-vs-etra →
SRZN Surrozen Inc.	E	27/100	—	—	-35.0%	-2.93%	$524.4M	/srzn-vs-etra →
RGNX REGENXBIO Inc.	D-	39/100	—	—	-35.0%	+2.35%	$489.2M	/rgnx-vs-etra →

2. ETRA Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Electra Therapeutics Inc. (ETRA) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $542.3M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. ETRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ETRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Electra Therapeutics Inc. (NASDAQ: ETRA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $8.64 (-3.79% 1D, market cap $542.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ETRA ranks #381 in composite RQD confidence.

How does ETRA compare to ENTX and VALN in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ETRA carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ENTX (Entera Bio Ltd.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -33.6%, cap $542.6M) and VALN (Valneva SE) posts a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $541.8M). Among the 5-stock peer group, ETRA leads on earnings multiple (N/A) while ENTX leads on capital efficiency (-33.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ETRA?

For Electra Therapeutics Inc. (ETRA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #381 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ETRA trading relative to its 50-day, 200-day, and 52-week technical levels?

ETRA last traded at $8.64 (-3.79% on volume of 166,477 shares), positioning the stock -13.60% below its 50-day simple moving average ($10.00) and -5.47% below its 200-day simple moving average ($9.14). Across its 52-week range of $7.95 to $15.50, ETRA sits at the 9.1% percentile with a 14-day RSI of 28.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($7.56 to $9.72).

ETRA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is ETRA's next earnings date?

Based on SEC filing cadence, Electra Therapeutics Inc. (ETRA)'s next quarterly reporting window is estimated around Upcoming Quarter.

How much is ETRA stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for ETRA, spanning a range between $7.56 and $9.72.

Direct Sub-Reports: ETRA RQD Cockpit ETRA 12M Forecast ETRA Earnings & Move ETRA Dividends & DRIP ETRA Insiders & 13F ETRA Whale Options ETRA Profit Sankey ETRA News & Why